Modulating the immune response to reduce hypertension-associated cardiovascular damage

Area of Science:

• Cardiovascular Medicine
• Immunology
• Pharmacology

Background:

• Cardiovascular diseases (CVDs) are a primary global cause of death and disability.
• Hypertension is a significant risk factor for CVDs, with limited effective treatments.
• Existing hypertension therapies often fail to fully address hypertension-mediated organ damage.

Purpose of the Study:

• To investigate the potential of developmental endothelial locus-1 (DEL-1) as a therapeutic agent for hypertension.
• To elucidate the mechanisms by which DEL-1 influences blood pressure and cardiovascular remodeling.
• To evaluate DEL-1's efficacy in mitigating hypertension-induced organ damage.

Main Methods:

• Utilized mouse models of hypertension.
• Administered endogenous anti-inflammatory agent developmental endothelial locus-1 (DEL-1).
• Assessed effects on blood pressure, cardiac and aortic hypertrophy, metalloproteinase activity, immune cell recruitment, and cytokine production.

Main Results:

• DEL-1 significantly decreased blood pressure in hypertensive mouse models.
• DEL-1 reduced cardiac and aortic hypertrophy, key indicators of cardiovascular damage.
• The observed effects were linked to reduced αvβ3 integrin-dependent metalloproteinase activity, decreased immune cell infiltration, and lower proinflammatory cytokine levels in cardiovascular tissues.

Conclusions:

• Developmental endothelial locus-1 (DEL-1) demonstrates potent antihypertensive effects.
• DEL-1 mitigates hypertension-mediated organ damage by modulating inflammatory pathways.
• DEL-1 represents a promising therapeutic candidate for treating hypertension and its associated cardiovascular complications.